• Country
    Clear
  • Compatibility Level
    Clear
  • Thematic
    Clear
  • Type
  • Jurisdiction

  • NL
  • EU
  • Not yet registered
  • Thematic: No

  • more_vert
  • more_vert
  • more_vert
  • The DARIAH-DE repository is a digital long-term archive for human and cultural-scientific research data. Each object described and stored in the DARIAH-DE Repository has a unique and lasting Persistent Identifier (DOI), with which it is permanently referenced, cited, and kept available for the long term. In addition, the DARIAH-DE Repository enables the sustainable and secure archiving of data collections. The DARIAH-DE Repository is not only to DARIAH-DE associated research projects, but also to individual researchers as well as research projects that want to save their research data persistently, referenceable and long-term archived and make it available to third parties. The main focus is the simple and user-oriented access to long-term storage of research data. To ensure its long term sustainability, the DARIAH-DE Repository is operated by the Humanities Data Centre.

    more_vert
  • more_vert
  • NeuronDB provides a dynamically searchable database of three types of neuronal properties: voltage gated conductances, neurotransmitter receptors, and neurotransmitter substances. It contains tools that provide for integration of these properties in a given type of neuron and compartment, and for comparison of properties across different types of neurons and compartments.

    more_vert
  • The Mitochondrial Disease Sequence Data Resource (MSeqDR) is a centralized genome and phenome bioinformatics resource built by the mitochondrial disease community to facilitate clinical diagnosis and research investigations of individual patient phenotypes, genomes, genes, and variants. It integrates community knowledge from expert‐curated databases with genomic and phenotype data shared by clinicians and researchers.

    more_vert
  • more_vert
  • Nearly 60% of patients undergoing cancer treatment are estimated to have had at least one potential drug-drug interaction; for patients receiving oral anticancer therapy, up to 50% have been reported to experience a potential drug-drug interaction, with 16% experiencing a major event. Drug-drug interactions are therefore a significant issue for cancer patients and the health care professionals who treat them. Combining the internationally recognised drug-drug interactions expertise of the University of Liverpool (UK) with the clinical pharmacology in oncology and haemotology expertise of Radboud University, Nijmegen (the Netherlands), this site was established in 2017 in response to the need for improved management of DDIs with anti-cancer agents.

    more_vert
  • more_vert
  • chevron_left
  • 1
  • 2
  • 3
  • 4
  • 5
  • chevron_right